This Project Grant award, issued by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $627,474 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research aimed at detecting and characterizing aggressive subtypes of prostate cancer, including treatment-emergent neuroendocrine prostate cancer (NEPC).
The research seeks to leverage innovative epigenomic profiling and single-cell analysis techniques to:
- Identify clinically relevant biomarkers in liquid biopsies to detect NEPC and predict resistance to the anti-androgen drug enzalutamide.
- Determine if aggressive NEPC cell subpopulations pre-exist in primary tumors prior to treatment.
- Develop an epigenomic classification system to enable earlier diagnosis and intervention for advanced prostate cancer.
The project, which runs from March 1, 2025 to February 28, 2030, is expected to advance understanding of lineage plasticity and treatment resistance in prostate cancer, leading to improved outcomes for this lethal disease.
Generated 3/18/25, 2:53 AM